Spinraza (Nusinersen) for Spinal Muscular Atrophy: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players – Biogen and Ionis Pharmaceuticals

Spinraza (Nusinersen) for Spinal Muscular Atrophy: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players - Biogen and Ionis Pharmaceuticals
DelveInsight Business Research LLP
DelveInsight has recently published a report on “Spinraza (Nusinersen) Market Forecast Report” providing an in-depth analysis of the Spinraza (Nusinersen) market analysis and forecasts up to 2032 in the seven major markets (7MM) (i.e. the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The comprehensive report provides an analysis of Spinraza (Nusinersen) market potential and market share analysis in the Spinal Muscular Atrophy therapeutics space across the 7MM from 2019 to 2032. The report also helps you to understand the Spinraza (Nusinersen) clinical and commercial developments along with parameters like the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.

Spinraza (Nusinersen) Drug Insight

SPINRAZA is being developed globally for the treatment of Spinal Muscular Atrophy (SMA). SPINRAZA is an antisense oligonucleotide (ASO) that is designed to treat Spinal Muscular Atrophy caused by mutations in the chromosome 5q that leads to SMN protein deficiency. SPINRAZA alters the splicing of SMN2 pre-mRNA in order to increase the production of full-length Spinal Muscular Atrophy protein. ASOs are short synthetic strings of nucleotides designed to selectively bind to target RNA and regulate gene expression. Through use of this technology, SPINRAZA has the potential to increase the amount of full-length SMN protein in patients with Spinal Muscular Atrophy.

Spinraza (Nusinersen) – Regulatory Development

On December 23, 2016, the United States Food and Drug Administration (FDA) granted approval for SPINRAZA (nusinersen), marking a historic milestone as the first drug sanctioned for the treatment of spinal muscular atrophy (SMA) in both pediatric and adult patients. The approved dosage for SPINRAZA injection stands at 12 mg (5 mL) per intrathecal administration.

The commencement of SPINRAZA treatment involves a loading phase consisting of four doses. The first three doses are administered at 14-day intervals, followed by the fourth dose, administered 30 days after the third loading dose. Subsequently, a maintenance dose of SPINRAZA should be administered once every four months to sustain therapeutic benefits.

The intrathecal administration of SPINRAZA, conducted over a period of 1 to 3 minutes, requires the expertise of healthcare professionals experienced in performing lumbar punctures. The drug’s administration regimen emphasizes the significance of precise medical supervision to ensure optimal efficacy and patient safety.

Stay ahead of the competition by leveraging key insights and evolving trends in the market @ 


Key Highlights of the Spinraza (Nusinersen) Market Report

  • The report includes a projected assessment of Spinraza (Nusinersen) sales for Spinal Muscular Atrophy up to the year 2032.
  • The report offers in-depth coverage of advanced-stage emerging therapies for the treatment of Spinal Muscular Atrophy.
  • The report additionally includes both qualitative and quantitative analyses conducted by analysts, along with Key Opinion Leader (KOL) perspectives on Spinraza (Nusinersen) for Spinal Muscular Atrophy.

Why Spinraza (Nusinersen) Market Report?

  • The projected market data for Spinraza (Nusinersen) in the context of Spinal Muscular Atrophy will play a crucial role in informing decision-making related to the therapeutic portfolio. It will provide valuable insights into the overall landscape of Spinraza (Nusinersen), aiding in strategic planning and decision-making processes within the therapeutic domain.
  • A comprehensive market forecast for Spinraza (Nusinersen) will contribute to a better understanding of how the drug competes with other emerging therapies within the therapeutics landscape. This analysis will provide insights into the drug’s positioning, potential market share, and overall impact on the competitive environment in the therapeutic field.
  • Conducting a thorough market forecast for Spinraza (Nusinersen) will facilitate a detailed analysis of the drug’s clinical trial progress. This examination will encompass a comprehensive assessment of the clinical, regulatory, and commercial aspects, providing valuable insights into the advancements of Spinraza (Nusinersen). 
  • The report additionally offers future market assessments for the Spinraza (Nusinersen) market in the field of Spinal Muscular Atrophy across the 7 Major Markets. It encompasses advanced qualitative analyses such as SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the realm of Spinal Muscular Atrophy. This multifaceted approach ensures a comprehensive understanding of the Spinraza (Nusinersen) market landscape, combining both quantitative and qualitative perspectives for a well-rounded assessment.

Request the Sample PDF to Learn More About the Key Offerings of the Spinraza (Nusinersen) Market Report @




Related Reports By DelveInsight:

Spinal Muscular Atrophy (SMA) Pipeline Insight

DelveInsight’s “Spinal Muscular Atrophy Pipeline Insight” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Spinal Muscular Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by routes of administration, and molecule types. Furthermore, it further highlights the inactive pipeline products in this space. Some of the key companies in the Spinal Muscular Atrophy Therapeutics market include ScholarRock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Therapeutics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Explore success with our case study on R&D, Manufacturing & Commercial Capabilities. Uncover insights for strategic growth in the industry @ https://www.delveinsight.com/case-study/r-and-d-landscape-assessment

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices